Last updated: September 14, 2026
Cabozantinib s-malate is the active pharmaceutical ingredient in Cabometyx and Cometriq, Exelixis’s oncology franchise. The business is driven primarily by Cabometyx in renal cell carcinoma, with additional demand from hepatocellular carcinoma and differentiated thyroid cancer. Exelixis reported approximately $1.85 billion in total revenue in 2023, with cabozantinib product sales representing the majority of commercial revenue. The franchise has a durable market position through the late 2020s, but faces increasing erosion risk from generic cabozantinib tablets after key U.S. patents expire or are settled.
What is cabozantinib s-malate and how is it commercialized?
Cabozantinib s-malate is the malate salt of cabozantinib, an oral tyrosine kinase inhibitor. It inhibits MET, VEGFR2, AXL, RET, and other kinases involved in tumor growth, angiogenesis, invasion, and resistance to prior therapy.
| Product |
Dosage form |
Primary indications |
Commercial rights |
| Cabometyx |
Oral tablets |
Renal cell carcinoma, hepatocellular carcinoma, differentiated thyroid cancer |
Exelixis in the United States; Ipsen in many international markets; Takeda in Japan |
| Cometriq |
Oral capsules |
Metastatic medullary thyroid cancer |
Exelixis in the United States; international rights vary |
Cabometyx is the strategic product. Cometriq was the original commercial formulation and has a substantially smaller market because medullary thyroid cancer is a narrower indication and the product is not interchangeable with Cabometyx tablets.
Cabozantinib is not a biologic. Biosimilar substitution is therefore not relevant. The principal post-exclusivity threat is conventional generic competition under an abbreviated new drug application, or ANDA.
What FDA approvals support the cabozantinib market?
The U.S. Food and Drug Administration has expanded cabozantinib from a thyroid-cancer product into a multi-indication solid-tumor franchise.
| FDA milestone |
Product or regimen |
Commercial significance |
| 2012 |
Cometriq for metastatic medullary thyroid cancer |
Initial U.S. approval |
| 2016 |
Cabometyx for advanced renal cell carcinoma after prior antiangiogenic therapy |
Established the larger tablet franchise |
| 2019 |
Cabometyx plus nivolumab for advanced renal cell carcinoma in the first-line setting |
Expanded use into treatment-naive patients |
| 2019 |
Cabometyx monotherapy for advanced renal cell carcinoma after prior therapy |
Broadened sequencing use |
| 2019 |
Cabometyx for hepatocellular carcinoma after prior sorafenib |
Added a second major solid-tumor market |
| 2021 |
Cabometyx for radioiodine-refractory differentiated thyroid cancer after prior VEGFR-targeted therapy |
Added a targeted thyroid-cancer segment |
The renal cell carcinoma indication is the commercial center of gravity. The combination with nivolumab competes directly with other first-line immune checkpoint inhibitor combinations, including pembrolizumab plus axitinib and pembrolizumab plus lenvatinib.
FDA labeling identifies cabozantinib as a small-molecule kinase inhibitor. The product carries clinically important risks, including hemorrhage, gastrointestinal perforation or fistula, thromboembolic events, severe diarrhea, palmar-plantar erythrodysesthesia, hypertension, hepatotoxicity, and impaired wound healing (U.S. Food and Drug Administration [FDA], 2024).
How large is the cabozantinib market and what is the revenue trajectory?
Cabozantinib has evolved from a niche thyroid-cancer medicine into a billion-dollar oncology franchise. Exelixis’s 2023 revenue was approximately $1.85 billion, compared with approximately $1.58 billion in 2022. Product revenue increased as Cabometyx gained share in renal cell carcinoma and maintained demand in hepatocellular and differentiated thyroid cancers (Exelixis, 2024).
| Fiscal year |
Exelixis total revenue |
Cabozantinib commercial position |
| 2021 |
Approximately $1.4 billion |
Growth from renal cell carcinoma and combination uptake |
| 2022 |
Approximately $1.58 billion |
Continued Cabometyx expansion |
| 2023 |
Approximately $1.85 billion |
Cabozantinib remained the core product franchise |
| 2024 onward |
Not included as a finalized historical figure here |
Growth depends on RCC share, international royalties, and new indications |
Cabozantinib product revenue is supported by several factors:
- Continued use after prior immune checkpoint inhibitor and VEGFR therapy.
- First-line adoption of Cabometyx plus nivolumab.
- Long treatment duration in advanced renal cell carcinoma.
- International sales and royalties under the Ipsen collaboration.
- Relatively limited direct generic competition before the principal U.S. patent runway ends.
The revenue profile is less dependent on a single launch event than it was earlier in the product lifecycle. It now depends on patient sequencing, combination treatment, and physician preference within renal cell carcinoma.
What is the financial exposure to renal cell carcinoma?
Renal cell carcinoma is the principal revenue driver because it has a larger addressable population than medullary thyroid cancer and has several lines of therapy in which cabozantinib is clinically relevant.
Cabometyx competes in:
- First-line advanced renal cell carcinoma with nivolumab.
- Later-line disease after immune checkpoint inhibitor exposure.
- Disease progressing after VEGFR-targeted therapy.
- Treatment settings where physicians favor a potent VEGFR and MET inhibitor.
The combination strategy creates both an opportunity and a risk. It increases use of cabozantinib, but commercial performance depends on nivolumab-based treatment algorithms and the competitive position of other checkpoint inhibitor combinations.
How does cabozantinib compare with competing renal cell carcinoma drugs?
| Drug or regimen |
Company |
Main competitive attribute |
Principal pressure on cabozantinib |
| Cabometyx plus nivolumab |
Exelixis and Bristol Myers Squibb |
First-line combination with established efficacy |
Faces direct competition from other immunotherapy combinations |
| Keytruda plus Lenvima |
Merck and Eisai |
Strong first-line efficacy and broad oncology presence |
Competes for treatment-naive RCC patients |
| Keytruda plus Inlyta |
Merck and Pfizer |
Established first-line RCC regimen |
Competes for prescribing share |
| Opdivo plus Yervoy |
Bristol Myers Squibb |
Immune-based regimen without a VEGFR TKI |
Can reduce early use of TKI combinations in selected patients |
| Lenvima monotherapy or combinations |
Eisai |
Potent VEGFR-directed activity |
Competes in later-line and combination treatment |
| Tivozanib |
AVEO, part of LG Chem |
Later-line VEGFR-focused therapy |
Competes in refractory RCC |
| Pazopanib and sunitinib |
Novartis and Pfizer |
Established VEGFR TKIs with generic availability |
Create price pressure and treatment alternatives |
Cabozantinib differentiates itself through activity against MET and AXL in addition to VEGFR targets. That profile is clinically relevant in disease biology associated with tumor invasion, angiogenesis, and treatment resistance. The commercial advantage is strongest in later-line disease and in patients who have received prior immune checkpoint therapy.
When does cabozantinib lose exclusivity in the United States?
Cabozantinib has layered patent protection rather than a single expiration date. The relevant exclusivity analysis separates regulatory exclusivity, compound patents, formulation or salt patents, method-of-use patents, and patent settlements.
Patent and exclusivity timeline
| Protection category |
Approximate timing |
Commercial effect |
| Cometriq initial approval |
2012 |
Narrower thyroid-cancer market |
| Cabometyx initial approval |
2016 |
Created the larger tablet franchise |
| Cabometyx composition and use patents |
Late 2020s to early 2030s |
Delay or restrict generic entry |
| U.S. regulatory exclusivity |
Largely expired for original indications |
Patent protection is more important than FDA exclusivity |
| Generic entry settlements |
Generally linked to negotiated future launch dates |
Can defer launch beyond the earliest patent expiration |
| Pediatric exclusivity |
Product-specific and indication-specific |
Any six-month extension must be confirmed against FDA records |
The key U.S. composition patent generally associated with Cabometyx is U.S. Patent No. 8,877,776. Its nominal expiration is in 2030, subject to patent-term adjustments, patent-term extension issues, and litigation outcomes. Other listed patents cover therapeutic uses and related aspects of cabozantinib treatment. The Orange Book remains the controlling source for the active patent listing and any associated pediatric exclusivity (FDA, 2024).
The practical generic-entry date may be later than the earliest nominal patent expiration because of:
- Multiple listed patents.
- Paragraph IV litigation.
- Agreed launch dates in settlements.
- Regulatory review timing.
- Potential authorized-generic arrangements.
- Different patent positions for Cabometyx tablets and Cometriq capsules.
What is the Orange Book status of Cabometyx and Cometriq?
Cabometyx is listed in the FDA Orange Book as a prescription tablet product with patents covering the drug substance, formulation, and approved methods of use. Cometriq is a separate capsule product with its own listing and regulatory history.
The products should not be treated as automatically interchangeable. Cabometyx tablets and Cometriq capsules differ in dosage form, strength presentation, formulation, and approved labeling. An ANDA for Cabometyx would face a different regulatory and patent analysis from an application directed to Cometriq.
The Orange Book status is commercially important because an ANDA applicant may file:
- Paragraph I certification if no patent is listed.
- Paragraph II certification if the patent has expired.
- Paragraph III certification accepting delayed approval until expiration.
- Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed.
A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman Act and may create a 30-month stay of FDA approval, subject to statutory exceptions (FDA, 2024).
Which companies are challenging cabozantinib patents?
Generic-drug manufacturers have shown interest in cabozantinib because of the product’s revenue scale and the prospect of a high-value U.S. launch. Publicly reported Hatch-Waxman activity has involved generic applicants and patent litigation against Exelixis, including proceedings concerning Cabometyx patents.
Relevant potential or reported challengers have included companies such as MSN Laboratories and other ANDA sponsors. Exelixis has used patent litigation and settlement agreements to protect the franchise. The commercial significance of any individual challenge depends on:
- The specific Cabometyx patent challenged.
- Whether the applicant seeks approval for all indications or a skinny-label indication.
- The court’s claim-construction and validity decisions.
- The settlement’s permitted launch date.
- Whether Exelixis provides an authorized generic.
Public litigation records should be reviewed case by case because a Paragraph IV notice does not establish that a generic will launch. Many challenges terminate through settlement before a final invalidity decision.
What patent litigation and settlement risks affect generic entry?
Cabozantinib generic entry has three primary scenarios.
Scenario 1: Delayed launch after settlement
This is the most commercially likely pathway when the branded company has enforceable patents and the generic applicant wants a defined launch date. The generic may receive a license to launch before the last patent expires but after the settlement date.
Scenario 2: At-risk launch
A generic company may launch before final resolution of all patent disputes. Exelixis could seek damages and injunctive relief. This strategy is less attractive when the brand has multiple patents and the product remains highly profitable.
Scenario 3: Court-ordered early entry
If a court invalidates or finds non-infringement of the key patents, FDA approval could lead to earlier generic competition. The economic impact would be substantial because the U.S. Cabometyx franchise carries high per-patient revenue and strong oncology demand.
A settlement can preserve branded revenue while giving the generic company a defined market-entry date. It can also include supply, authorized-generic, or other commercial terms that affect the size of post-exclusivity price erosion.
How strong is the cabozantinib patent estate?
The patent estate is commercially meaningful but not immune to challenge.
Strengths
- A high-value oncology franchise supports aggressive litigation.
- Multiple patents create layered defenses.
- Method-of-use patents can protect important RCC treatment settings.
- The product has multiple dosage strengths and formulations.
- Cabometyx has a broader commercial base than the original Cometriq product.
Weaknesses
- The active pharmaceutical ingredient is a small molecule, so generic substitution is technically feasible.
- Regulatory exclusivity for the earliest approvals has largely run its course.
- Method-of-use patents may be vulnerable to skinny-label strategies.
- Generic applicants can challenge patent validity through Paragraph IV certifications.
- International patent protection varies by country and does not create a uniform global barrier.
The strongest commercial protection is the combination of patent litigation, settlement control, clinical adoption, and manufacturing know-how. Manufacturing complexity alone is unlikely to prevent a capable generic manufacturer from producing cabozantinib tablets after patent barriers fall.
What formulations and manufacturing factors are protected?
Cabometyx is an oral tablet containing cabozantinib s-malate. The formulation differs from Cometriq capsules and should be analyzed separately for patent and regulatory purposes.
Potentially relevant intellectual-property categories include:
- The cabozantinib chemical entity.
- The s-malate salt.
- Tablet composition and excipients.
- Dissolution and stability characteristics.
- Dosage strengths.
- Methods for treating RCC, HCC, and differentiated thyroid cancer.
- Combination use with nivolumab.
- Manufacturing processes and impurity controls.
The manufacturing barrier is moderate. Cabozantinib is a synthetic small molecule rather than a biologic requiring cell-line development, complex folding control, or biosimilarity studies. Generic manufacturers would generally rely on pharmaceutical equivalence, bioequivalence, and CMC demonstrations rather than clinical efficacy trials.
What licensing deals support the cabozantinib market?
Exelixis has used regional licensing to expand cabozantinib outside the United States.
| Partner |
Region or role |
Strategic effect |
| Ipsen |
Rights in markets outside the United States and Japan, subject to agreement terms |
Provides international commercialization and milestone or royalty economics |
| Takeda |
Japan commercialization rights |
Supports Japanese market access |
| Bristol Myers Squibb |
Nivolumab combination collaboration |
Connects Cabometyx to a major immuno-oncology regimen |
Ipsen is a major commercial partner because it markets cabozantinib in numerous international territories. The arrangement allows Exelixis to monetize the asset through collaboration revenue and royalties while limiting the need to build a full global sales infrastructure.
The Bristol Myers Squibb relationship is strategically important because Cabometyx plus nivolumab is central to first-line RCC positioning. The economics depend on collaboration terms, geographic sales, and the allocation of development and commercial responsibilities.
What generic launch risks exist for cabozantinib?
The generic risk profile is gradual rather than immediate.
| Period |
Risk level |
Main driver |
| Before core patent settlements expire |
Low to moderate |
Paragraph IV filings and litigation without broad market entry |
| Near negotiated launch dates |
Moderate to high |
One or more authorized or independent generics may enter |
| After core patents expire |
High |
Multi-source generic substitution and price compression |
| After broad generic penetration |
Very high for U.S. revenue |
Reduced net price, formulary substitution, and market-share loss |
Initial generic entry could produce a sharp decline in branded U.S. sales even if Exelixis retains some share through contracting, physician preference, or an authorized-generic strategy. Oncology products often experience rapid price erosion when several manufacturers enter, although the pace varies by product complexity and the number of approved suppliers.
Cabometyx’s multiple indications may slow erosion if generic labeling does not initially cover every use. A skinny-label generic could still capture prescriptions where the patented method is not required, while branded Cabometyx remains necessary for protected indications.
What is the international exclusivity outlook?
International exclusivity is fragmented. Patent terms, supplementary protection certificates, regulatory data exclusivity, local litigation, and reimbursement systems differ by country.
Ipsen’s territories may experience generic entry at different times from the United States. Europe can see accelerated erosion after national or regional patent barriers expire, while Japan is governed by its own patent and regulatory framework. Emerging markets may face earlier competition if local patent protection is weak or if generic approval pathways are more permissive.
The commercial value of international sales is therefore less predictable than the U.S. franchise. U.S. patent settlements and launch dates should not be assumed to apply globally.
What is the long-term commercial outlook for cabozantinib?
Cabozantinib is likely to remain a major oncology asset through the late 2020s. Growth depends on maintaining renal cell carcinoma share, expanding use after prior immunotherapy, protecting combination economics, and developing additional indications.
The principal risks are:
- Generic entry after patent settlements or expiration.
- Intensifying competition from lenvatinib, axitinib, tivozanib, and other VEGFR inhibitors.
- Reduced use of TKI combinations in favor of emerging immunotherapy regimens.
- Treatment sequencing changes in renal cell carcinoma.
- Pressure on international prices.
- Clinical differentiation challenges in hepatocellular carcinoma and thyroid cancer.
The principal supports are:
- A broad approved indication base.
- Strong positioning in post-immunotherapy RCC.
- Combination use with nivolumab.
- Established physician familiarity.
- International licensing revenue.
- A patent estate extending into the late 2020s and, for selected rights, the early 2030s.
Key Takeaways
- Cabozantinib s-malate is marketed primarily as Cabometyx tablets and, in a separate formulation, Cometriq capsules.
- Cabometyx is the dominant commercial product, with renal cell carcinoma as its main revenue driver.
- Exelixis generated approximately $1.85 billion in total revenue in 2023, with cabozantinib accounting for most commercial value.
- The U.S. market has layered patent protection, including composition and method-of-use patents.
- A representative Cabometyx composition patent, U.S. Patent No. 8,877,776, has a nominal expiration in 2030.
- Paragraph IV challenges and settlements are the main mechanisms shaping generic entry.
- Cabozantinib is a small molecule, so biosimilar risk does not apply. Conventional ANDA generic risk is the relevant threat.
- Ipsen and Takeda expand the franchise internationally, while Bristol Myers Squibb supports the nivolumab combination.
- Generic erosion is likely to be gradual before the core patent runway ends and rapid once multiple suppliers enter.
FAQs About Cabozantinib S-Malate
Is cabozantinib s-malate the same as Cabometyx?
Yes. Cabometyx contains cabozantinib s-malate as its active pharmaceutical ingredient. Cabozantinib s-malate is the salt form used in the marketed tablet.
Is Cometriq interchangeable with Cabometyx?
No. Cometriq capsules and Cabometyx tablets are separate FDA-approved products with different dosage forms, formulations, strengths, and labeling.
Can a generic manufacturer make cabozantinib tablets?
Yes. Cabozantinib is a synthetic small molecule, and a generic manufacturer could seek FDA approval through an ANDA after resolving applicable patents and demonstrating pharmaceutical equivalence and bioequivalence.
Does nivolumab extend cabozantinib patent protection?
No. The nivolumab combination may be protected by separate method-of-use or regimen patents, but it does not automatically extend every patent covering cabozantinib or Cabometyx.
What is the biggest investment risk for the cabozantinib franchise?
The largest risk is U.S. generic entry after patent litigation or settlement, followed by loss of renal cell carcinoma share to competing immunotherapy and VEGFR-directed regimens.
References
- Exelixis, Inc. (2024). 2023 annual report and Form 10-K.
- U.S. Food and Drug Administration. (2024). Cabometyx prescribing information.
- U.S. Food and Drug Administration. (2024). Cometriq prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Exelixis, Inc. (2024). Cabometyx and cabozantinib corporate product information.
- U.S. Patent No. 8,877,776. (2014). Compounds and methods for the treatment of cancer. United States Patent and Trademark Office.
